Feng Wang is a Research Associate in the Jones Lab. He earned his M.D. in Clinical Medicine from Norman Bethune University of Medical Science in China, and completed his Ph.D. in Pathology, Immunology, and Microbiology at The University of Tokyo in Japan. His doctoral research focused on the regulation of cancer cell signaling through 5-phosphatase-mediated phosphoinositide metabolism. Prior to joining the Jones Lab, Feng worked as a Senior Scientist at a biopharmaceutical company in New York, where he developed cellular, biochemical, and pharmacological assays to characterize the mechanisms of action of drug candidates. He also served as a Faculty Associate in the Department of Oncology at Albert Einstein College of Medicine, where he investigated the functional role and signaling pathways of a novel oncogenic mutation, MET exon 14 skipping, in tumor growth and metastasis. Additionally, as a Research Fellow at Memorial Sloan-Kettering Cancer Center, Feng led a preclinical study exploring the efficacy of combination therapy involving an anti-angiogenic inhibitor and single-dose radiotherapy (SDRT) on sarcoma tumors. Currently, Feng is actively involved in various research projects, including studies utilizing humanized mouse models of HIV infection and exploring the resistance of CD4+ T cells harboring HIV to Cytotoxic T lymphocyte (CTL) killing.